Actively Recruiting
Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
Led by Sun Yat-sen University · Updated on 2025-12-31
1124
Participants Needed
23
Research Sites
540 weeks
Total Duration
On this page
Sponsors
S
Sun Yat-sen University
Lead Sponsor
T
The First Affiliated Hospital of Nanchang University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Video-assisted thoracic surgery (VATS) has been recommended by clinical guidelines as one of the preferred surgeries for early-stage non-small cell lung cancer (NSCLC) for many years. However, VATS has inherent drawbacks, so at the beginning of this century, robotic-assisted thoracoscopic surgery (RATS) was first applied for lung resection. In recent years, RATS has developed rapidly, but there are still many unsolved scientific problems in the field of RATS. Thus, a multicenter prospective randomized controlled trial was conducted with stage I-II NSCLC patients as the study subject and 5-year DFS as the primary endpoint to compare the short-term and long-term outcomes of RATS and VATS in the treatment of early-stage NSCLC.
CONDITIONS
Official Title
Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age from 18 to 80 years old
- Blood pressure below 160/100 mmHg and blood glucose between 5.6 and 11.2 mmol/L
- Normal major organ function including Goldman index grade 1 or 2
- Predicted forced expiratory volume in 1 second (FEV1) of 40% or more and lung diffusing capacity (DLCO) of 40% or more
- Total bilirubin less than or equal to 1.5 times the upper limit of normal
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 times the upper limit of normal
- Creatinine less than or equal to 1.25 times the upper limit of normal and creatinine clearance rate (CCr) 60 ml/min or higher
- First clinical diagnosis before surgery of non-small cell lung cancer, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, or other unknown types
- Clinical stage T1-2N0-1 (stage I-II) with tumor size 5 cm or less and mediastinal lymph node size 1 cm or less on thin-layer CT
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Completion of all relevant examinations within 28 days before surgery
- Ability to understand the study and provide informed consent
You will not qualify if you...
- Previous radiotherapy, chemotherapy, targeted therapy, or immunotherapy before surgery
- History of other malignancies
- Presence of secondary primary cancer at enrollment
- Diagnosis of pure ground glass opacity (GGO) before surgery
- Diagnosis of mixed GGO with solid part 50% or less and tumor size 2 cm or less
- Small cell lung cancer diagnosis
- Prior unilateral open thoracic surgery
- Pregnant or breastfeeding women
- Interstitial pneumonia, pulmonary fibrosis, or severe emphysema
- Active bacterial or fungal infection that is difficult to control
- Serious psychosis
- History of severe heart attack, heart failure, myocardial infarction, or angina within the last 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 23 locations
1
First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400014
Actively Recruiting
2
Gansu Provincial Hospital
Lanzhou, Gansu, China, 730000
Actively Recruiting
3
The Second Hospital of Lanzhou University
Lanzhou, Gansu, China, 730030
Actively Recruiting
4
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
5
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510080
Actively Recruiting
6
Shenzhen People's Hospital
Shenzhen, Guangdong, China, 518020
Actively Recruiting
7
Shenzhen Third People's Hospital
Shenzhen, Guangdong, China, 518112
Actively Recruiting
8
Guangxi Nanxishan Hospital
Guilin, Guangxi, China, 541002
Actively Recruiting
9
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450052
Actively Recruiting
10
Wuhan Union Hospital
Wuhan, Hubei, China, 430022
Actively Recruiting
11
Wuhan TongJi Hospital
Wuhan, Hubei, China, 430030
Actively Recruiting
12
The General Hospital of Eastern Theater Command
Nanjing, Jiangsu, China, 210002
Actively Recruiting
13
Jiangsu Cancer Institute & Hospital
Nanjing, Jiangsu, China, 210009
Actively Recruiting
14
Jiangxi Provincial People's Hopital
Nanchang, Jiangxi, China, 330006
Actively Recruiting
15
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330006
Actively Recruiting
16
Liaoning Tumor Hospital & Institute
Shenyang, Liaoning, China, 110042
Actively Recruiting
17
Tang-Du Hospital
Xi'an, Shaanxi, China, 710038
Actively Recruiting
18
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250012
Actively Recruiting
19
Qianfoshan Hospital
Jinan, Shandong, China, 250014
Actively Recruiting
20
Shandong Provincial Hospital
Jinan, Shandong, China, 250022
Actively Recruiting
21
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China, 266003
Actively Recruiting
22
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, China, 610041
Actively Recruiting
23
West China Hospital
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
H
Hao-Xian Yang, M.D.
CONTACT
M
Mu-Zi Yang, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here